Published April 4, 2022
We are announcing a revised IRB fee schedule for research studies that are supported by for-profit entities and WashU serves as the IRB. The last fee increase occurred in 2015.
The new fee schedule is listed below (Table 1) and becomes effective for all reviews as of July 1, 2022. These fees reflect current peer institution and industry standards. We have also included our current fee schedule (Table 2) for comparison purposes.
Table 1: Revised IRB Fees
Effective July 1, 2022
| Type of Form | New Fees |
|---|---|
| New Submission | $3,000 |
| Modifications | $750 |
| Continuing Reviews | $1,750 |
Requests to change consent injury language incur an additional $750 charge regardless of other changes requested.
A modification fee is not assessed for research team member changes.
Table 2: Current IRB Fees
| Type of Form | Current Fees |
|---|---|
| New Submission | $2,500 |
| Modifications | $500 |
| Continuing Reviews | $1,500 |
Requests to change consent injury language incur an additional $500 charge regardless of other changes requested.
The Human Research Protection Office (HRPO) currently charges for IRB review of any research studies that are supported by for-profit companies. This includes:
- For-profit supported studies, including PI initiated studies
- Industry supported studies
- Both clinical trials or non-clinical trials
Payment of IRB reviewing fees is required for all research studies that receive financial support from a for-profit entity, regardless of the designation of the support.
IRB fees are non-refundable. The fees are an assessment for the administrative costs associated with IRB review and HRPO operations. Because HPRO commits its full resources to each review, the fees are due in full, even if the study is not approved, is withdrawn after submission, participants are never enrolled, a research contract is never executed, or the study is terminated before the study objectives are achieved. HRPO requires payment of the fees prior to releasing the study for accrual.
Questions regarding the fee policy may be directed to me or Jeanne Velders, Executive Director of HRPO.
Richard J. Stanton
Vice Chancellor Medical Finance and Administration